Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dengzhan Shengmai Capsule in coronary heart disease with HFpEF
ChiCTR2300072852Phase 4Recruiting
- Sponsor
- Xiyuan Hospital
- Start
- Jun 2023
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Dengzhan Shengmai in coronary arteriosclerosis and heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by Xiyuan Hospital. Primary endpoint: Six-minute walk test distance. Started Jun 2023; status: recruiting.
02
Drugs
Dengzhan Shengmai
03
Conditions
coronary arteriosclerosisheart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on ChiCTR2300072852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072852.